%0 Journal Article
%@ 1472-4472
%A Ding, C
%A Li, J
%A Zhang, X
%D 2004
%F epprod:3608
%J Current Opinion in Investigational Drugs
%N 11
%P 1213-1219
%T Bertilimumab (Cambridge Antibody Technology Group)
%U http://eprints.utas.edu.au/3608/
%V 5
%X Cambridge Antibody Technology (CAT) is developing
bertilimumab, an anti-eotaxin-1 monoclonal antibody, for the potential treatment of allergic disorders. By September 2003, CAT had released results from phase I/II trials, and was seeking to outlicense rights for bertilimumab.